Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The North America anti-obesity drugs market size is expected to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity and the growing demand for effective anti-obesity drugs with fewer side effects in the region.
Anti-obesity drugs are expected to aid in weight management with minimal side effects by inducing fat absorption, appetite suppression, and metabolic enhancement, among others. In North America, there is a rising acceptance of obesity as a chronic disease requiring medical intervention rather than just lifestyle changes. This shift in perception coupled with heightened patient awareness and the presence of advanced healthcare infrastructure in the region is expected to contribute to the North America anti-obesity drugs market growth.
Recent data suggests that obesity rates in North America are sharply increasing. In the United States, 41.9% of adults are estimated to be obese, out of which, Black and Latino populations have the highest rates of obesity at 49.9% and 45.6%, respectively. The rising prevalence of obesity impacts the demand for effective and affordable anti-obesity therapeutics significantly. Furthermore, the increased focus on research in obesity management to combat the growing cases in the region is anticipated to boost market size in coming years.
One of the significant North America anti-obesity drugs market trends is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Eli Lilly and Company manufactured Zepbound (containing the active ingredient tirzepatide). It is designed for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. Zepbound is known to activate certain hormone receptors in the intestine that reduce food intake and suppress appetite. Its efficacy was evaluated in two randomized controlled trials which showed that Zepbound can result in a statistically significant reduction in body weight. The increased availability of such effective anti-obesity drugs is likely to elevate market value.
The market is witnessing increased merger and acquisition initiatives from the key market players. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative therapeutics, thereby fuelling North America anti-obesity drugs market demand. In September 2023, Novo Nordisk A/S acquired a Canada-based biotechnology company, called Inversago Pharma in a deal worth over USD 1 billion. The partnership was intended to expand its obesity and diabetes portfolio. The company also aims to assess the potential of Inversago’s lead candidate, INV-202, which is known to block the CB1 receptor involved in the regulation of appetite and metabolism, in obesity and associated complications. Such substantial investments in the anti-obesity drug pipelines are expected to improve access to obesity treatments, which will positively impact the market share.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup | Categories |
Drugs | Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide |
Drug Class | Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor |
Mechanism of Action | Centrally Acting Drugs, Peripherally Acting Drugs |
Route of Administration | Oral, Subcutaneous |
Prescription Type | Prescription Drugs, Over the Counter Drugs |
Distribution Channel | Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies |
Countries | United States of America, Canada |
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drugs |
|
Breakup by Drug Class |
|
Breakup by Mechanism of Action |
|
Breakup by Route of Administration |
|
Breakup by Prescription Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity in the region.
The increasing awareness about the health risks associated with obesity and the rising disposable incomes in the region are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication.
Based on the drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.
Drug classes available in the market include amphetamine, GLP-1 receptor agonists, and lipase inhibitors.
By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.
The market breakup by route of administration includes oral and subcutaneous.
Based on the prescription type, the market includes prescription drugs and over-the-counter drugs.
Distribution channels of the market include hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceutical LLC (Currax Holdings USA LLC), Vivus LLC, Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH), and KVK Tech, Inc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124